Immunome (IMNM) Cash & Equivalents (2019 - 2026)

Immunome (IMNM) has 8 years of Cash & Equivalents data on file, last reported at $582.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 126.19% year-over-year to $582.7 million; the trailing twelve-month figure through Mar 2026 stood at $582.7 million (up 126.19% YoY), and the FY2025 full-year result was $653.5 million, up 355.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $582.7 million, down from $653.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $653.5 million in Q4 2025 and bottomed at $20.3 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $143.4 million (2024), against an average of $178.9 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 58.72%; it then surged 507.16% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $20.3 million in 2022, then soared by 385.55% to $98.7 million in 2023, then surged by 45.27% to $143.4 million in 2024, then surged by 355.86% to $653.5 million in 2025, then dropped by 10.83% to $582.7 million in 2026.
• The last three Cash & Equivalents figures came in at $582.7 million (Q1 2026), $653.5 million (Q4 2025), and $272.6 million (Q3 2025), per Business Quant data.

Peer Comparison